2021
Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial
Sposito A, Breder I, Soares A, Kimura-Medorima S, Munhoz D, Cintra R, Bonilha I, Oliveira D, Breder J, Cavalcante P, Moreira C, Moura F, de Lima-Junior J, do Carmo H, Barreto J, Nadruz W, Carvalho L, Quinaglia T. Dapagliflozin effect on endothelial dysfunction in diabetic patients with atherosclerotic disease: a randomized active-controlled trial. Cardiovascular Diabetology 2021, 20: 74. PMID: 33771149, PMCID: PMC8004411, DOI: 10.1186/s12933-021-01264-z.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBenzhydryl CompoundsBiomarkersBlood GlucoseBrazilCarotid Artery DiseasesDiabetes Mellitus, Type 2Drug Therapy, CombinationEndothelium, VascularFemaleGlucosidesGlyburideGlycated HemoglobinHumansMaleMetforminMiddle AgedProspective StudiesSodium-Glucose Transporter 2 InhibitorsTime FactorsTreatment OutcomeVasodilationConceptsFlow-mediated dilationSodium-glucose cotransporter-2 inhibitorsCoprimary endpointsAtherosclerotic diseaseWeeks of therapyResultsNinety-seven patientsMacrovascular endothelial functionCotransporter-2 inhibitorsType 2 diabetes mellitusRandomized active-controlled trialActive-controlled trialCarotid intima-media thicknessRandomized clinical trialsIntima-media thicknessDapagliflozin EffectGlibenclamide armsDapagliflozin groupArterial wall functionOpen-labelSGLT2i treatmentGlibenclamide groupResultsNinety-sevenSingle-centerMedian HbA1cCarotid atherosclerotic disease
2013
Impact of Seasonality on the Prevalence of Dyslipidemia: A Large Population Study
Moura F, Dutra-Rodrigues M, Cassol A, Parra E, Zago V, Panzoldo N, Alexandre F, Vieira I, Vendrame F, Virginio V, Castanho V, Danelon M, Nunes V, Leança C, Saraiva F, Coelho O, Nakandakare E, Quintão E, de Faria E, Sposito A. Impact of Seasonality on the Prevalence of Dyslipidemia: A Large Population Study. Chronobiology International 2013, 30: 1011-1015. PMID: 23837747, DOI: 10.3109/07420528.2013.793698.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge DistributionAge FactorsAgedAged, 80 and overBiomarkersBrazilChildChild, PreschoolCholesterol, HDLCholesterol, LDLCross-Sectional StudiesDyslipidemiasFemaleHumansInfantInfant, NewbornMaleMiddle AgedNonlinear DynamicsPeriodicityPrevalenceRisk FactorsSeasonsSex DistributionSex FactorsTime FactorsTriglyceridesYoung AdultConceptsLDL-CHDL-CLipoprotein cholesterolLipid profileLow-density lipoprotein cholesterolPlasma low-density lipoprotein cholesterolHigh-density lipoprotein cholesterolPrevalence of dyslipidemiaAnalysis of relative riskLipid profile parametersVariation of lipid profilePrimary care centersLipid parametersRate of goal achievementCross-sectional analysisConsecutive individualsRelative riskCardiovascular diseaseCare centerHealth checkupsMiddle-aged adultsTriglyceridesBiological rhythmsPreliminary dataPrevalence
2011
High plasma HDL-C attenuates stress hyperglycemia during acute phase of myocardial infarction
Carvalho L, Cintra R, Moura F, Martins N, Quinaglia e Silva J, Coelho O, Sposito A, Group O. High plasma HDL-C attenuates stress hyperglycemia during acute phase of myocardial infarction. Atherosclerosis 2011, 220: 231-236. PMID: 22018645, DOI: 10.1016/j.atherosclerosis.2011.09.044.Peer-Reviewed Original ResearchConceptsHDL-C levelsHDL-C quartilePlasma HDL-C levelsHDL-CC-peptideMyocardial infarctionAcute phaseStress hyperglycemiaInsulin sensitivityAssociated with HDL-C levelsConsecutive non-diabetic patientsNon-diabetic patientsAcute phase of MILow plasma HDL-C levelsAcute phase of myocardial infarctionST-segment elevationPhase of myocardial infarctionBeta-cell functionAssess insulin sensitivityPhase of MIImproved insulin sensitivityBlood glucose changesPlasma glucoseQuartilePlasma insulin